City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  412  Clinical trial(s) found  (Page 1 of 17 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 18389 ClinicalTrials.gov Number: NCT03709706

Principal Investigator: Karen Reckamp, MD
Sponsor: Industry

Title:  A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

COH Protocol Number: 18382

Principal Investigator: Kim Margolin, MD
Sponsor: Industry

Title:  A Phase II, Open-label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab Versus Penbrolizumab in Patients with Previously Untreated Advanced Melanoma

COH Protocol Number: 18380

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Pilot Study to Evaluate Substances in Sweat, Saliva, and Blood

COH Protocol Number: 18376 ClinicalTrials.gov Number: NCT03640481

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industry

Title:  A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After at Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

COH Protocol Number: 18361

Principal Investigator: Brooke Crawford, MD
Sponsor: Institutional

Title:  Robot Assistance for CT Guided Needle Placement

COH Protocol Number: 18358

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Blood Samples to Identify Biomarkers for Post-transplant Cyclophosphamide

COH Protocol Number: 18356

Principal Investigator: Tanya Dorff, MD
Sponsor: Industry

Title:  A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)

COH Protocol Number: 18355 ClinicalTrials.gov Number: NCT03558087

Principal Investigator: Sumanta Pal, MD
Sponsor: Institutional

Title:  Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

COH Protocol Number: 18346 ClinicalTrials.gov Number: NCT03568461

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industry

Title:  A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients with Refractory or Relapsed Follicular Lymphoma

COH Protocol Number: 18344 ClinicalTrials.gov Number: NCT03761056

Principal Investigator: Alex Herrera, MD
Sponsor: Externally Peer-Reviewed

Title:  A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High- Risk Large B-Cell Lymphoma (ZUMA-12)

COH Protocol Number: 18335 ClinicalTrials.gov Number: NCT03634982

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industry

Title:  A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors

COH Protocol Number: 18334 ClinicalTrials.gov Number: NCT03126630

Principal Investigator: Marianna Koczywas, MD
Sponsor: National

Title:  PHII-175 NCI# 10107 Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

COH Protocol Number: 18329 ClinicalTrials.gov Number: NCT03662659

Principal Investigator: Joseph Chao, MD
Sponsor: Industry

Title:  A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma

COH Protocol Number: 18328 ClinicalTrials.gov Number: NCT03597581

Principal Investigator: Marwan Fakih, MD
Sponsor: Industry

Title:  A Phase 1 Study of RGX-202-01, A Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts

COH Protocol Number: 18324 ClinicalTrials.gov Number: NCT03589469

Principal Investigator: Jasmine Zain, MD
Sponsor: Industry

Title:  A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

COH Protocol Number: 18317 ClinicalTrials.gov Number: NCT03713320

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industry

Title:  SOLAR: A Phase 2 Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

COH Protocol Number: 18311

Principal Investigator: Marwan Fakih, MD
Sponsor: Institutional

Title:  Expanded Access Protocol for HS, RXDX-105 for the Treatment of a Patient with Non-Small Cell Lung Cancer (NSCLC) Harboring a CCDCD6-RET Gene Fusion

COH Protocol Number: 18309 ClinicalTrials.gov Number: NCT03375320

Principal Investigator: Daneng Li, MD
Sponsor: Other

Title:  Alliance A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)

COH Protocol Number: 18306

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Food Deserts and Insulin Resistance

COH Protocol Number: 18305 ClinicalTrials.gov Number: NCT03776253

Principal Investigator: Anne Reb, RN, PhD
Sponsor: Institutional

Title:  Conquer Fear SUPPORT: A Psychosocial Intervention in Patients with Advanced Cancer

COH Protocol Number: 18299

Principal Investigator: Alex Herrera, MD
Sponsor: Industry

Title:  A Phase I/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

COH Protocol Number: 18295

Principal Investigator: Veronica Jones, MD
Sponsor: Institutional

Title:  Predictors of Chemoresistance in Locally Advanced Luminal B Breast Cancer

COH Protocol Number: 18294

Principal Investigator: Arya Amini, MD
Sponsor: Institutional

Title:  Geriatric Assessment and Quality of Life in Older Adults Undergoing Chemoradiation for Head and Neck Cancer and Their Family Caregivers

COH Protocol Number: 18289 ClinicalTrials.gov Number: NCT03504397

Principal Investigator: Joseph Chao, MD
Sponsor: Industry

Title:  A Phase 3, Global, Multi-Center, Double- Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

COH Protocol Number: 18282 ClinicalTrials.gov Number: NCT03669718

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industry

Title:  A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.